Investigation on the Maternal-Infantile Infection with Human Parvovirus B19

To investigate the maternal-infantile infection with human parvovirus B19, the IgG and IgM antibodies against human parvovirus and the B19-DNA in serum and peripheral blood mononuclear cells (PBMC) of pregnant women as well as the serum IgM antibody against B19 and the B19-DNA in serum and cord blood nucleated cells (CBNC) of newborns were determined by ELISA and nested PCR respectively. It was found that the positive rate of the IgG antibody against human parvovirus B19 in sera of 92 pregnant women was 38.04% (35/92), and that of the IgM antibody in 720 pregnant women was 9.03% (65/720). However, the IgM antibody against human parvovirus B19 was negative in the cord blood sera of 95 newborns. As to the human parvovirus B19 DNA, none of 720 pregnant women and 95 newborns was proved to be positive in their sera. Nevertheless, the positive rate of the parvovirus B19 DNA in PBMC was 3.06% (3/98) in 98 pregnant women and 1.12% (1/89) in CBNC of 89 newborns. It is concluded that the history of infection with human parvovirus B19 exists in certain pregnant women with a small percentage of pregnant women infected with recent or acute infections of B19 virus. The detection rates of the B19 viral DNA in PBMC of pregnant women and CBNC of newborns were higher than those in sera, indicating that the risk for vertical transmission is very low.

Acute encephalitis and encephalopathy associated with human parvovirus B19 infection in children

Reports of neurologic manifestations of human parvovirus B19(B19) infection have been on the rise. Acute encephalitis and encephalopathy is the most common, accounting for 38.8% of total B19-associated neurological manifestations. To date, 34 children with B19encephalitis and encephalopathy have been reported, which includes 21 encephalitis and 13 encephalopathy cases. Ten(29%) were immunocompromised and 17(39%) had underlying diseases. Fever at the onset of disease and rash presented in 44.1% and 20.6% of patients, respectively. Neurological manifestations include alteration of consciousness occurred in all patients, seizures in 15(44.1%) patients, and focal neurologic signs in 12(35.3%) patients. Anemia and pleocytosis in cerebrospinal fluid(CSF) occurred in 56.3% and 48.1% of patients, respectively. Serum Anti-B19 Ig M(82.6%) and CSF B19 DNA(90%) were positive in the majority of cases. Some patients were treated with intravenous immunoglobulins and/or steroids, although an accurate evaluation of the efficacy of these treatment modalities cannot be determined. Nineteen(57.6%) patients recovered completely, 11(33.3%) patients had some neurological sequelae and 3(8.8%) patients died. Although the precise pathogenesis underlying the development of B19 encephalitis and encephalopathy is unclear, direct B19 infection or NS1 protein of B19 toxicity in the brain, and immune-mediated brain injuries have been proposed.

人微小病毒B19感染的研究进展

近年来人微小病毒B19(human parvovirus B19)作为人类疾病的重要病原已愈来愈广泛受到重视。大量研究成果不但揭示了B19病毒的致病机理,Th-1介导的细胞免疫应答,而且发展了B19感染的诊断和B19污染血制品的筛查技术,并且为疫苗的研制奠定了基础。这里对人类B19病毒的病原学特征、致病机理、临床症状及实验室诊断方法和技术进行了较全面的综述。

儿童微小病毒B19感染的诊断与治疗

人微小病毒B19经常感染儿童,临床表现复杂,轻者表现为自限性的传染性红斑,重者可因血细胞减少而导致患儿死亡。在免疫缺陷的患儿可发生持续感染。文章对改进其诊断和治疗,作了探讨。

青岛市区产妇、新生儿人类细小病毒B_(19)感染状况研究

[目的 ]了解青岛市区产妇及新生儿中人类细小病毒B1 9的感染状况。 [方法 ]采用巢式聚合酶链反应方法对配对的 3 2 3对产妇血清及其新生儿的脐带血清进行检测。 [结果 ] 3 2 3名产妇中有 6例B1 9病毒DNA阳性 ,阳性率为0 3 1%。 [结论 ]青岛市区的B1 9病毒感染率低于文献报道的国内外其他地区的感染率。